Migrating with myosin VI

American Journal of Pathology

Volumn 169, Issue 5, 2006, Pages 1523-1526

  Knudsen, Beatrice ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYOSIN VI; MESSENGER RNA; MYOSIN HEAVY CHAIN; TUMOR MARKER;

CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL POLARITY; ENDOCYTOSIS; GENE EXPRESSION; HUMAN; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR GENE;

CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MALE; MYOSIN HEAVY CHAINS; PROSTATIC NEOPLASMS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 38749109982     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.060712     Document Type: Note

References (34)

1. Dunn TA, Chen S, Faith DA, Hicks JL, Platz EA, Chen Y, Ewing CM, Sauvageot J, Isaacs WB, De Marzo AM, Luo J: A novel role of myosin VI in human prostate cancer. Am J Pathol 169:1843-1854
2. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, Gray JW, Mills GB: The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 2004, 10:1251-1256
3. Buss F, Luzio JP, Kendrick-Jones J: Myosin VI, an actin motor for membrane traffic and cell migration. Traffic 2002, 3:851-858
4. Hasson T: Myosin VI: two distinct roles in endocytosis. J Cell Sci 2003, 116:3453-3461
5. De Marzo AM, Marchi VL, Epstein JI, Nelson WG: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999, 155:1985-1992
6. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V: Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004, 6:185-195
7. Gao CF, Xie Q, Su YL, Koeman J, Khoo SK, Gustafson M, Knudsen BS, Hay R, Shinomiya N, Vande Woude GF: Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci USA 2005, 102:10528-10533
8. Putzi MJ, De Marzo AM: Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000, 56:828-832
9. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB, Nelson WG: Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004, 91:459-477
10. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, Isaacs WB: Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001, 61:8617-8623
11. Parsons JK, Nelson CP, Gage WR, Nelson WG, Kensler TW, De Marzo AM: GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue. Prostate 2001, 49:30-37
12. Jung EJ, Liu G, Zhou W, Chen X: Myosin VI is a mediator of the p53-dependent cell survival pathway. Mol Cell Biol 2006, 26:2175-2186
13. Davies JA: Watching tubules glow and branch. Curr Opin Genet Dev 2005, 15:364-370
14. Buss F, Luzio JP, Kendrick-Jones J: Myosin VI, a new force in clathrin mediated endocytosis. FEBS Lett 2001, 508:295-299
15. Aschenbrenner L, Naccache SN, Hasson T: Uncoated endocytic vesicles require the unconventional myosin, Myo6, for rapid transport through actin barriers. Mol Biol Cell 2004, 15:2253-2263
16. Buss F, Arden SD, Lindsay M, Luzio JP, Kendrick-Jones J: Myosin VI isoform localized to clathrin-coated vesicles with a role in clathrin-mediated endocytosis. EMBO J 2001, 20:3676-3684
17. Morris SM, Arden SD, Roberts RC, Kendrick-Jones J, Cooper JA, Luzio JP, Buss F: Myosin VI binds to and localises with Dab2, potentially linking receptor-mediated endocytosis and the actin cytoskeleton. Traffic 2002, 3:331-341
18. Inoue A, Sato O, Homma K, Ikebe M: DOC-2/DAB2 is the binding partner of myosin VI. Biochem Biophys Res Commun 2002, 292:300-307
19. Yang DH, Fazili Z, Smith ER, Cai KQ, Klein-Szanto A, Cohen C, Horowitz IR, Xu XX: Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-null background. Am J Pathol 2006, 169:258-267
20. Chen H, Toyooka S, Gazdar AF, Hsieh JT: Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem 2003, 278:3121-3130
21. Buss F, Kendrick-Jones J, Lionne C, Knight AE, Cote GP, Paul Luzio J: The localization of myosin VI at the golgi complex and leading edge of fibroblasts and its phosphorylation and recruitment into membrane ruffles of A431 cells after growth factor stimulation. J Cell Biol 1998, 143:1535-1545
22. Warner CL, Stewart A, Luzio JP, Steel KP, Libby RT, Kendrick-Jones J, Buss F: Loss of myosin VI reduces secretion and the size of the Golgi in fibroblasts from Snell's waltzer mice. EMBO J 2003, 22:569-579
23. Geisbrecht ER, Montell DJ: Myosin VI is required for E-cadherinmediated border cell migration. Nat Cell Biol 2002, 4:616-620
24. Montell DJ: Command and control: regulatory pathways controlling invasive behavior of the border cells. Mech Dev 2001, 105:19-25
25. Montell DJ: Border-cell migration: the race is on. Nat Rev Mol Cell Biol 2003, 4:13-24
26. Pinheiro EM, Montell DJ: Requirement for Par-6 and Bazooka in Drosophila border cell migration. Development 2004, 131:5243-5251
27. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB: Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001, 61:4683-4688
28. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J: Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001, 61:5692-5696
29. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson Jr HF, Hampton GM: Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer, Cancer Res 2001, 61:5974-5978
30. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412:822-826
31. Faith DA, Isaacs WB, Morgan JD, Fedor HL, Hicks JL, Mangold LA, Walsh PC, Partin AW, Platz EA, Luo J, De Marzo AM: Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate 2004, 61:215-227
32. Garraway IP, Seligson D, Said J, Horvath S, Reiter RE: Trefoil factor 3 is overexpressed in human prostate cancer. Prostate 2004, 61:209-214
33. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM: Metaanalysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002, 62:4427-4433
34. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004, 101:811-816